$173MSeries A and BMarrow Therapeutics launches with $173M to send genetic medicines straight to bone marrow
OrbiMed led a $120 million Series B on top of a $53 million Series A co-led by Scion Life Sciences and venBio. Marrow's lead drug, for sickle cell disease and beta thalassemia, is in IND-enabling studies.













